ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...

NEW YORK, Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors are advised to ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

We recently compiled a list of the 10 Best UK Stocks to Invest in Now. In this article, we are going to take a look at where ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

At the close in Stockholm, the OMX Stockholm 30 lost 1.01%. The best performers of the session on the OMX Stockholm 30 were ...

Fed delivered the widely expected 25 bps rate cut yesterday. A pause in rate cuts can't be ruled out in December. See my ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating on November 6. Andrew ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.